1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)heptane-3,5-diol | 919090-22-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)heptane-3,5-diol
• CAS: 919090-22-5
• 化学式: C₂₀H₂₆O₅
• 分子量: 346.4
• InChiKey: BFNDWBVORMUOIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  90.2
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• CURCUMINOID COMPOSITION FOR THERAPEUTIC MANAGEMENT OF METABOLIC SYNDROME
  申请人：Majeed Muhammed

  公开号：US20210106543A1

  公开（公告）日：2021-04-15

  The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.
• CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS
  申请人：Majeed Muhammed

  公开号：US20210106544A1

  公开（公告）日：2021-04-15

  The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.
• [EN] CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS<br/>[FR] COMPOSITION DE CURCUMINOÏDE ET SON POTENTIEL THÉRAPEUTIQUE DANS LA PRISE EN CHARGE DE LA FIBROSE PULMONAIRE
  申请人：MAJEED MUHAMMED

  公开号：WO2021076771A1

  公开（公告）日：2021-04-22

  The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w7w hexahydrocurcuminoids and 5%- 10% w7w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.
• [EN] CURCUMINOID COMPOSITION FOR THERAPEUTIC MANAGEMENT OF METABOLIC SYNDROME<br/>[FR] COMPOSITION DE CURCUMINOÏDES DESTINÉE À LA PRISE EN CHARGE THÉRAPEUTIQUE DU SYNDROME MÉTABOLIQUE
  申请人：MAJEED MUHAMMED

  公开号：WO2021076766A1

  公开（公告）日：2021-04-22

  The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%- 10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.